|
 The rejection comes four months after U.S. patent officials
invalidated three patents on its drug Copaxone, in response to
challenges by pharmaceutical company Mylan NV, which has been trying
to market a generic version of the drug.
All asserted claims of Teva were invalid, the U.S. District Court Of
Delaware said in a ruling on Monday.
The patents, which expire in 2030, cover a 40-milligram injection of
Copaxone that patients administer three times a week.
Generics may only be sold after a drug's patents expire or are
invalidated through litigation.
However, Teva said it planned to appeal the decision.
[to top of second column] |
U.S.-listed shares of Teva were down almost 9 percent in after-hours
trading, while Mylan's shares edged up marginally.
(Reporting by Sruthi Shankar and Sangameswaran S in Bengaluru;
Editing by Bill Rigby)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
